Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.40 |
| ▸ | RXRA | P19793 | 1/20 | 0.40 |
| ▸ | RXRB | P28702 | 1/20 | 0.40 |
| ▸ | TPMT | P51580 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2656280 | 0.91 | KMT2A (0.52) | MAPTKMT2AALOX15TSHRHIF1A | |
| SCHEMBL30017038 | 0.85 | TPMT (0.38) | MAPTKMT2AALOX15TSHRHIF1A | |
| SCHEMBL21349298 | 0.85 | TPMT (0.38) | MAPTKMT2AALOX15TSHRHIF1A | |
| SCHEMBL2657835 | 0.84 | KDM4E (0.55) | KMT2AALOX15TSHRHIF1ACYP1A2 | |
| SCHEMBL16727015 | 0.83 | KDM4E (0.54) | MAPTKMT2ATSHRSMN1; SMN2MEN1 | |
| SCHEMBL2658290 | 0.81 | KMT2A (0.43) | MAPTKMT2AALOX15TSHRHIF1A | |
| SCHEMBL18359920 | 0.81 | CA12 (0.47) | MAPTKMT2ATSHRSMN1; SMN2MEN1 | |
| SCHEMBL5365414 | 0.80 | ALDH1A1 (0.58) | ALOX15TSHRHIF1ASMN1; SMN2CYP1A2 | |
| SCHEMBL31550344 | 0.80 | ALDH1A1 (0.58) | ALOX15TSHRHIF1ASMN1; SMN2CYP1A2 | |
| SCHEMBL19330159 | 0.80 | MAPT (0.49) | MAPTKMT2AALOX15TSHRHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017004609-A1 | THIADIAZOLE MODULATORS OF S1P AND METHODS OF MAKING AND USING | EXELIXIS, INC. (US) | 2017-01-05 | — | — | WO | disclosed |
| US-8598208-B2 | Pyridine derivatives as S1P1/EDG1 receptor modulators | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-12-03 | — | — | US | disclosed |
| US-8580824-B2 | Pyridin-4-yl derivatives as immunomodulating agents | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-11-12 | — | — | US | disclosed |
| US-8580824-B2 | Pyridin-4-yl derivatives as immunomodulating agents | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-11-12 | — | — | US | disclosed |
| US-8580824-B2 | Pyridin-4-yl derivatives as immunomodulating agents | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-11-12 | — | — | US | disclosed |
| EP-2069336-B1 | PYRIDIN-4-YL DERIVATIVES AS IMMUNOMODULATING AGENTS | ACTELION PHARMACEUTICALS LTD (CH) | 2012-12-26 | — | — | EP | disclosed |
| EP-2069336-B1 | PYRIDIN-4-YL DERIVATIVES AS IMMUNOMODULATING AGENTS | ACTELION PHARMACEUTICALS LTD (CH) | 2012-12-26 | — | — | EP | disclosed |
| US-20110212998-A1 | PYRIDINE DERIVATIVES AS S1P1/EDG1 RECEPTOR MODULATORS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-09-01 | — | — | US | disclosed |
| US-20110212998-A1 | PYRIDINE DERIVATIVES AS S1P1/EDG1 RECEPTOR MODULATORS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-09-01 | — | — | US | disclosed |
| US-20110212998-A1 | PYRIDINE DERIVATIVES AS S1P1/EDG1 RECEPTOR MODULATORS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-09-01 | — | — | US | disclosed |
| EP-2195311-B1 | PYRIDINE DERIVATIVES AS S1P1/EDG1 RECEPTOR MODULATORS | ACTELION PHARMACEUTICALS LTD (CH) | 2011-03-23 | — | — | EP | disclosed |
| EP-2195311-A1 | PYRIDINE DERIVATIVES AS S1P1/EDG1 RECEPTOR MODULATORS | Actelion Pharmaceuticals Ltd. (CH) | 2010-06-16 | — | — | EP | disclosed |
| US-20100063108-A1 | Pyridin-4-yl derivatives as immunomodulating agents | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-03-11 | — | — | US | disclosed |
| US-20100063108-A1 | Pyridin-4-yl derivatives as immunomodulating agents | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-03-11 | — | — | US | disclosed |
| US-20100063108-A1 | Pyridin-4-yl derivatives as immunomodulating agents | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-03-11 | — | — | US | disclosed |
| EP-2069336-A1 | PYRIDIN-4-YL DERIVATIVES AS IMMUNOMODULATING AGENTS | Actelion Pharmaceuticals Ltd. (CH) | 2009-06-17 | — | — | EP | disclosed |
| WO-2009024905-A1 | PYRIDINE DERIVATIVES AS S1P1/EDG1 RECEPTOR MODULATORS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-02-26 | — | — | WO | disclosed |
| WO-2009024905-A1 | PYRIDINE DERIVATIVES AS S1P1/EDG1 RECEPTOR MODULATORS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-02-26 | — | — | WO | disclosed |
| WO-2008029371-A1 | PYRIDIN-4-YL DERIVATIVES AS IMMUNOMODULATING AGENTS | ACTELION PHARMACEUTICALS LTD (CH) | 2008-03-13 | — | — | WO | disclosed |
| WO-2008029371-A1 | PYRIDIN-4-YL DERIVATIVES AS IMMUNOMODULATING AGENTS | ACTELION PHARMACEUTICALS LTD (CH) | 2008-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063108-A1 | Pyridin-4-yl derivatives as immunomodulating agents | CD4, FCGRT, IL2 | MAPT 4035/4885KMT2A 2657/4885ALOX15 1459/4885 |
| US-20110212998-A1 | PYRIDINE DERIVATIVES AS S1P1/EDG1 RECEPTOR MODULATORS | S1PR1, S1PR3, S1PR2 | MAPT 3603/4885KMT2A 2397/4885ALOX15 1212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.